

Diabetes Associated Ophthalmic Treatment Market Report 2025-2034: Rising to USD 69.09 Billion at a 6.90% CAGR

Diabetes Associated Ophthalmic Treatment Market size was worth around USD 35.45 billion in 2024 and is predicted to grow to around USD 69.09 billion by 2034

PUNE, MAHARASHTRA, INDIA, August 5, 2025 /EINPresswire.com/ -- □ Executive Summary


The [global diabetes-associated ophthalmic treatment market](#) was valued at approximately USD 35.45

billion in 2024 and is projected to reach USD 69.09 billion by 2034, growing at a steady compound annual growth rate (CAGR) of 6.90% over the forecast period (2025–2034). This growth is fueled by the rising global diabetes burden, increased awareness about diabetic eye complications, and technological advancements in ophthalmic therapeutics.

“

Diabetes associated ophthalmic treatment market size was worth around USD 35.45 billion in 2024 and is predicted to grow to around USD 69.09 billion by 2034, (CAGR) of 6.90% between 2025 and 2034.”

Deepak Rupnar



Diabetes Associated Ophthalmic Treatment Market

Elevate your business strategy with comprehensive market data. Request a sample report now:

<https://www.zionmarketresearch.com/sample/diabetes-associated-ophthalmic-treatment-market>

□ Market Overview

Diabetes mellitus significantly increases the risk of various ocular disorders, most notably diabetic retinopathy, macular edema, cataracts, and glaucoma. With over half a billion people affected by diabetes worldwide, the need for

targeted ophthalmic treatment has become a critical healthcare concern.

Diabetes-related vision loss is one of the leading causes of blindness in adults. Prompt diagnosis and innovative treatment options—ranging from anti-VEGF therapies to laser photocoagulation

and minimally invasive surgeries—are vital in preventing permanent damage and enhancing quality of life.

Key Insights:

As per the analysis shared by our research analyst, the global diabetes associated ophthalmic treatment market is estimated to grow annually at a CAGR of around 6.90% over the forecast period (2025-2034)

In terms of revenue, the global diabetes associated ophthalmic treatment market size was valued at around USD 35.45 billion in 2024 and is projected to reach USD 69.09 billion by 2034.

The diabetes associated ophthalmic treatment market is projected to grow at a significant rate due to the growing number of diabetic patients worldwide.

Based on the type, the drugs segment is growing at a high rate and will continue to dominate the global market as per industry projections.

Based on the application, the diabetes retinopathy segment is anticipated to command the largest market share.

Based on region, Asia-Pacific is projected to dominate the global market during the forecast period.

Do You Have Any Query Or Specific Requirement? Request Customization of Report:

<https://www.zionmarketresearch.com/custom/9536>


□ Market Dynamics

□ Market Drivers

Rising Global Prevalence of Diabetes

An alarming increase in Type 1 and Type 2 diabetes is directly linked to a surge in vision-threatening complications.

Global Diabetes Associated Ophthalmic Treatment Market, 2020-2034 (USD Billion)



Source: Zion Market Research

Zion
Market Research

Diabetes Associated Ophthalmic Treatment Market Size



THE GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET



BAUSCH Health

Johnson & Johnson

Kodiak
Sciences Inc.

Santen



Genentech
A Member of the Roche Group



REGENERON
PHARMACEUTICALS INC.



REGENERON
PHARMACEUTICALS INC.

Alcon

Diabetes Associated Ophthalmic Treatment Market Regional Analysis

Technological Advancements in Diagnostics & Treatment

AI-based fundus imaging, OCT (Optical Coherence Tomography), and smart retinal scanning are improving early detection and precision treatment.

Increased Awareness and Screening Programs

Government and NGO-led campaigns are promoting regular eye checkups and diabetic retinopathy awareness.

Growing Geriatric Population

Ageing adults are at higher risk of both diabetes and age-related eye diseases, contributing to higher demand for treatment solutions.

□ Market Segmentation

By Treatment Type

Anti-VEGF Therapy (e.g., Ranibizumab, Aflibercept, Bevacizumab)

Corticosteroids (e.g., Dexamethasone Implants)

Laser Therapy

Surgical Interventions

Combination Therapies

By Indication

Diabetic Retinopathy

Diabetic Macular Edema (DME)

Glaucoma

Cataracts

By End User

Hospitals

Ophthalmic Clinics

Ambulatory Surgical Centers (ASCs)

Homecare Settings

By Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

□ Regional Insights

□ North America

Largest market share due to high diabetes prevalence, access to advanced healthcare, and key market players.

Presence of structured reimbursement policies and awareness programs.

□ Europe

Strong growth supported by aging population and universal healthcare systems.

Active involvement of research institutions and regulatory approvals for new therapies.

□ Asia-Pacific

Fastest-growing region due to growing diabetic population in China and India.

Increasing investments in healthcare infrastructure and teleophthalmology.

□ Latin America & Middle East

Gradual increase in awareness and healthcare spending.

Efforts underway to improve early diagnosis and accessibility.

Inquiry For Buying-<https://www.zionmarketresearch.com/inquiry/diabetes-associated-ophthalmic-treatment-market>

□ Key Market Players

The global diabetes associated ophthalmic treatment market is led by players like:

Pfizer Inc.

F. Hoffmann-La Roche Ltd

Bausch Health Companies Inc.

EyePoint Pharmaceuticals Inc.

Johnson & Johnson Services Inc.

Kodiak Sciences Inc.

Santen Pharmaceutical Co. Ltd.

Ocular Therapeutix Inc.

Novartis AG

Genentech Inc.

AbbVie Inc.

Oxurion NV

Bayer AG

Regeneron Pharmaceuticals Inc.

Alcon Inc.

These companies are involved in strategic collaborations, new drug launches, and clinical trials targeting diabetic ophthalmic conditions.

□ Recent Developments

2024: Regeneron's aflibercept 8 mg gains FDA approval for extended-interval dosing for DME.

2025: AI-driven diagnostic platforms by Novartis introduced in Asia for rural diabetes eye screenings.

2025: Kubota Vision announces successful trial of a wearable retinal imaging device for diabetic retinopathy.

□□ Market Challenges

High Cost of Treatments and Devices
Limited Access in Low-Income Regions
Lack of Skilled Ophthalmologists in Developing Nations
Patient Non-Adherence to Regular Eye Exams

□ Future Outlook

The next decade will witness a shift from reactive to preventive eye care in diabetes management. Integration of AI-based early detection, sustained-release drug delivery systems, and teleophthalmology will be central to expanding access and improving outcomes. The market will also benefit from gene therapies, nanotech-based delivery, and biomarker-driven treatment plans, redefining standards in vision preservation for diabetic patients.

□ Conclusion

The Diabetes-Associated Ophthalmic Treatment Market is set to nearly double over the next decade, driven by the urgency to address diabetes-related vision loss and the rise in cutting-edge therapeutic solutions. Stakeholders across pharma, med-tech, and public health sectors must collaborate to close the care gap and ensure sight-saving treatment reaches every patient in need.

More Trending Reports by Zion Market Research -

[US Diabetes Devices Market](#)

[Drug-Device Combination Products Market](#)

Deepak Rupnar

Zion Market Research

+1 855-465-4651

richard@zionmarketresearch.com

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/837106605>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.